header image

Noticias Recientes

Octapharma donates 30.5 million international units of its medicine Nuwiq® to treat people with haemophilia in developing countries

21.11.2017

Lachen, Switzerland, November 21st, 2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in...

Octapharma USA Grant Supports Mission of First Hemophiliac to Climb the Seven Summits of the World

02.11.2017

Hoboken, New Jersey, October 31st 2017: Octapharma USA has provided a grant to support the final leg of the inspirational journey of Chris Bombardier, who hopes to become the first person with severe Hemophilia to climb...

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

31.08.2017

Hoboken, New Jersey, August 29th 2017: Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with...

Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in previously untreated patients

23.08.2017

Lachen, Switzerland, August 23rd 2017: Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously...

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium

07.04.2017

HOBOKEN, N.J. (April 7, 2017) – Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island....

Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million

01.03.2017

Lachen, Switzerland, March 1st, 2017: The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015. Octapharma achieved sales...